Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of SCTC21C in systemic lupus erythematosus
CTR20261382Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTC21C in systemic lupus erythematosus (SLE), sponsored by Sinocelltech Group Limited. Started Apr 2026; status: active.
02
Drugs
SCTC21C
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20261382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261382.